TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Pethidine requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term forgetting of numeric materials
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Progression of kyphosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Sympathetic activity variations during SWCCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: anatomic and visual improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ag85A-specific IFNγ T cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: multifunctional CD4+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical Remission (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Endoscopic Remission (ER)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: microbiological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of wheeze
Endpoint domain: Adverse events/effects
Primary endpoint: Epidural scar adhesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Recurrence rate of paroxysmal atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean frequency of migraine attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abortive drug usage per week
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Testing positive for Chlamydia and/or gonorrhea
Endpoint domain: Adverse events/effects
Primary endpoint: DASS-anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of inappropriate shocks
Endpoint domain: Adverse events/effects
Primary endpoint: Limbal redness improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eyelid redness improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of neuroleptic treatment change
Endpoint domain: Adverse events/effects
Primary endpoint: Global assessment of improvement from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjects' evaluation of local tolerability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subjects' global preference
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of daily defecations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: awareness of performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: improved attitudes towards the guideline
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: increased self-efficacy beliefs in managing patients with low back pain
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: breast cancer incidence rate
Endpoint domain: Mortality/survival
Primary endpoint: PCRn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 90-day modified Rankin scale scores 2-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oral corticosteroid bursts
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Median volume increase in both cheeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: local IGF-I expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of severe corneal opacities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission from depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive mental health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cardiac death-free rate
Endpoint domain: Mortality/survival
Primary endpoint: Post-operative ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mouth dryness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall sensation of symptom relief
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HCV/HIV-related knowledge improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean change scores of clinical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade 2-4 leukopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Median leukocyte value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: first-attempt intubation success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of patients who had a relapse
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients with confirmed progression of disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flow-mediated dilatation (FMD) of the radial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Eligibility based on visual field test requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction of Postoperative Hospitalization and Functional Decline (PHFD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality at Day 28
Endpoint domain: Mortality/survival
Primary endpoint: average reaction time for cash withdrawals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity for cash withdrawals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: specificity for cash withdrawals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cure rates for H. pylori infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of nausea and retching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of re-intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time of ICU stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-operative and post-operative IOP control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Bleb characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Plasma total antioxidant status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Post-operative abdominal PAC-SYM subscale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reported strain during bowel movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Type 1 Bristol stool on first post-operative bowel movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: lower percent fat in abdominal and leg regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: increase in fat-free mass in leg and gynoid regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: increase in mitochondrial capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in foreign body sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in fluorescein staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in TFBUT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: systemic exposure to beclometasone‐17‐monopropionate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: systemic exposure to formoterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of reflux related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of reoperations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Need for antisecretory drug therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Serum Progesterone Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: recurrence rate at 3 years
Endpoint domain: Mortality/survival
Primary endpoint: patient satisfaction at 1 and 3 years
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: pain during last week at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patients' global assessment of symptoms
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: mean change in creatinine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Hemoglobin levels >11 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality at 30 days, 6 and 12 months
Endpoint domain: Mortality/survival
Primary endpoint: self-evaluation after failure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Interpretation of physical findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum sodium from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Panretinal leakage index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: motivation and attitudes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Role‐Physical
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: episodes of bloody diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cumulative incidence of recurrent UO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete vertigo control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decolonization of S. aureus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: ADHD symptom trajectory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functioning 6 to 8 years later
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: significant impairment in adolescence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Gastric liquid emptying rate (GLER)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Diagnostic accuracy of EUS for T stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean duration of nocturnal acid breakthrough
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: medical-care cost-reductions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Granulocyte elastase serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: AOFAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: temporary interruption of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death or spontaneous second myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Estimates of time passage
Endpoint domain: Cognitive functioning
Primary endpoint: Number of correction boluses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Effectiveness of 25 mg hydrocortisone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain coping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fear reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Meal-related symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastroesophageal symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastric emptying improvement (T(max) value)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Numeric working memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Word recognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Adenoma Detection Rate (ADR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Boston Bowel Preparation Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GADA titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to clinical diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of OPIS implementation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: SPID-8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of meal-stimulated gastric acid secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Moderate to Vigorous Physical Activity (MVPA) during school days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sedentary Behavior (SB) during lesson time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Good functional recovery at six months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Favourable outcome (GOS 4-5) at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Favourable outcome (GOS 4-5) at 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atelectasis requiring bronchoscopy
Endpoint domain: Adverse events/effects
Primary endpoint: Skin complications associated with vascular access devices
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum postoperative GFR decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: ankle dorsiflexion mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal isometric strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: resistance to plantar flexor stretch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite end-point achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to achieve normoprolactinemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumour shrinkage of ≥50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of patients recurrence free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean annual number of recurrences per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: False-positive PSA test rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biopsy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aggressiveness of prostate cancer tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Size of WSL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dmft index values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severe ototoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in absolute CD4+ cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Suppression of plasma HIV RNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Active gene transcription (SC-35 positive area)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: conversion of AF to sinus rhythm for at least 1 minute within 90 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time savings for patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction of propofol infusion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stress response to surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cytoplasmic pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receipt of psychotherapy services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Systolic cardiac function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VO(2-peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients wanting to speak to a specialist smoking adviser
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Presence of varices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-mile walk time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-walk heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Natural cell-mediated cytotoxicity (NCMC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: alanine aminotransferase (ALT) normalization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of repetitions performed in the final set to failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective markers of fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Mean power output during anaerobic sprint test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of rescue anti-pruritic medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mental health QOL improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of oral microflora
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Defensin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Myocardial ischemia detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of secondary cataract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: retrospective reporting of mental disorders
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: bacterial adhesion scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bacterial MRHA negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevention of recurrent urinary tract infections (r-UTI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Tumor conspicuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Dose-length product
Endpoint domain: Physiological/clinical
Endpoint subdomain: Radiation exposure outcomes
Primary endpoint: clinically significant change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number and complexity of ventricular arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Return to normal walking and stair climbing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRP level decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Spontaneous platelet aggregation change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: frequency of sexual activity and pleasure-orgasm
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Psychological General Well-Being Index scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: more smoke-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reductions in carbon monoxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma E and NE levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintaining opioid abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Scale (VAS) ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of hallucinations and agitation
Endpoint domain: Adverse events/effects
Primary endpoint: Patient-centered communication components
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CD34(+)/CD133(+) cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes